Copyright
        ©2014 Baishideng Publishing Group Inc.
    
    
        World J Biol Chem. Nov 26, 2014; 5(4): 409-428
Published online Nov 26, 2014. doi: 10.4331/wjbc.v5.i4.409
Published online Nov 26, 2014. doi: 10.4331/wjbc.v5.i4.409
            Table 1 Implications of BDNF in brain-related diseases
        
    | BDNF expression levels in brain diseases andanimal models | Possible involvement of BDNF in therapies | 
| Alzheimer’s disease (patients) | |
| Decreased expression levels of BDNF mRNA | |
| Hippocampus: ref.[147,148] | |
| Cortex: ref.[148,149] | |
| Decreased expression levels of BDNF protein | |
| Serum: ref.[152] | |
| Hippocampus: ref.[150] | |
| Cortex: ref.[150,151]; no change ref.[247] | |
| Alzheimer’s disease (animal models) | Alzheimer’s disease (animal models) | 
| Decreased expression levels of BDNF mRNA | BDNF gene delivery ameliorated age-related cognitive impairment in aged primates and rats. ref.[153] | 
| Cortex: Aβ transgenic strains | 7, 8-DHF improved memory deficits in 5XFAD transgenic mouse. ref.[156] | 
| (APPNLh and TgCRND8) ref.[155] | |
| Decreased expression levels of BDNF protein | |
| Hippocumpus: 5XFAD transgenic mouse ref.[156] | |
| Huntington disease (patients) | |
| Decreased expression levels of BDNF mRNA | |
| Serum: ref.[165] | |
| Cortex: ref.[162] | |
| Caudate: decreased TrkB mRNA ref.[162] | |
| Decreased expression levels of BDNF protein | |
| Cortex: ref.[163,165] | |
| Striatum: ref.[163] | |
| Cerebellum: ref.[163] | |
| Substantia nigra: ref.[163] | |
| Caudate and Putamen: ref.[164] | |
| Huntington disease (animal models) | Huntington disease (animal models) | 
| Decreased expression levels of BDNF mRNA | BDNF overexpression improved motor function in R6/2 mice. ref.[167] | 
| Cortex: R6/2 mice, ref.[166,167] | BDNF overexpression ameliorated YAC128 mice phenotype. ref.[168] | 
| Decreased expression levels of BDNF protein | Environmental enrichment-increased BDNF improved the phenotype in R6/1 mice. ref.[169] | 
| Striatum: YAC128 mice, ref.[168]; | Sertraline-increased BDNF improved the phenotype in R6/2 mice. ref.[170] | 
| R6/1 mice ref.[169] | 7, 8-DHF or 4’-DMA-7,8-DHF improved motor deficits in N171-82Q mice. ref.[171] | 
| Depression (patients) | Depression (patients) | 
| Decreased expression levels of BDNF mRNA | Antidepressants increased BDNF in serum. ref.[191-193,248] | 
| Hippocampus: ref.[185] (suicidal) | Antidepressants increased BDNF and TrkB in the cerebellum. ref.[194] | 
| Cortex: ref.[185] (suicidal), | |
| decreased TrkB mRNA ref.[188] | |
| Amygdala: ref.[187] | |
| Decreased expression levels of BDNF protein | |
| Serum: ref.[189-191] | |
| Hippocampus ref.[185] (suicidal)[186] (suicidal) | |
| Cortex: ref.[185] (suicidal)[186] (suicidal) | |
| Depression (animal models) | Depression (animal models) | 
| Decreased expression levels of BDNF mRNA | Antidepressants increased BDNF in the rat brain | 
| Hippocampus: social defeat stress, ref.[195]; | Tricyclic antidepressants (TCA; including imipramine, desipramine), ref.[202-204] | 
| restrain stress, ref.[196,197] (also TrkB); | Selective serotonin reuptake inhibitors (SSRI; fluoxetine, paroxetine, sertraline), ref.[202,204-206,251] | 
| maternal deprivation, ref.[198]; | Noradrenergic and specific serotonergic antidepressants (NaSSA; mirtazapine, mianserin), ref.[202,207] | 
| dexamethasone, ref.[199]; | Monoamine oxidase inhibitors (MAOIs; tranylcypromine), ref.[202-204] | 
| corticosterone, ref.[196,200,201]; | |
| foot shock stress, ref.[249] | |
| Cortex: social defeat stress, ref.[195]; | Electroconvulsive seizures induced BDNF expression. ref.[202,208-211] | 
| maternal deprivation, ref.[198]; | 7,8-DHF showed an antidepressant-like effect. ref.[212] | 
| dexamethasone, ref.[199]; | Direct BDNF infusion into the rat midbrain induced antidepressant-like effects. ref.[213] | 
| cold swim stress, ref.[250] | |
| Amygdala: social defeat stress, ref.[193] | |
| Decreased expression levels of BDNF protein | |
| Hippocampus: maternal deprivation, ref.[198]; | |
| corticosterone, ref.[200,201]; | |
| cold swim stress, ref.[250] | |
| Schizophrenia (patients) | Schizophrenia (patients) | 
| Decreased expression levels of BDNF mRNA | Clozapine treatment increased serum BDNF mRNA levels. ref.[235,236] | 
| Serum: ref.[236,252]; | |
| decreased TrkB mRNA ref.[253] | |
| Cortex: ref.[122,233,254,255]; | |
| decreased TrkB mRNA ref.[255]; | |
| incrased trunkated TrkB mRNA ref.[256] | |
| Serum: ref.[235,257-260] | |
| Hippocampus: ref.[231]; | |
| abnormal expression of TrkB ref.[261]; | |
| increased BDNF mRNA ref.[230] | |
| Cortex: ref.[232-234]; | |
| increase BDNF mRNA ref.[230,231] | |
| Cerebrospinal fluid ref.[234] | |
| Schizophrenia (animal models) | Schizophrenia (animal models) | 
| Decreased expression levels of BDNF mRNA | Mk-801-induced decline in hippocampal BDNF mRNA was normalized by olanzapine, but exacerbated by haloperidol. ref.[238] | 
| Hippoaumpus: phencyclidine, ref.[238]; | Haloperidol or risperidone decreased BDNF protein in the rat frontal cortex and hippocampus. ref.[241] | 
| MK-801 ref.[239]; | Haloperidol decreased BDNF and TrkB protein in the rat hippocampus. ref.[242] | 
| ibotenic acid lesions, ref.[240] | Risperidon, olanzapine, haloperidol, and chlorpromazine decreased BDNF levels in the rat striatum and hippocampus. ref.[243] | 
| Cortex: phencyclidine, ref.[238] | Haloperidol down-regulated BDNF mRNA expression in the rat hippocampus. ref.[262] | 
| Amygdala: phencyclidine, ref.[238] | 
- Citation: Adachi N, Numakawa T, Richards M, Nakajima S, Kunugi H. New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases. World J Biol Chem 2014; 5(4): 409-428
 - URL: https://www.wjgnet.com/1949-8454/full/v5/i4/409.htm
 - DOI: https://dx.doi.org/10.4331/wjbc.v5.i4.409
 
